Document:

Exclusive License Agreement

 Exhibit 10.17 
 EXCLUSIVE LICENSE AGREEMENT 
 Between 

NanoString Technologies, Inc. 
 (Licensee) 
 And 

The Institute for Systems Biology 
 (INSTITUTE) 
 This Exclusive License Agreement (hereinafter called
“Agreement”), is entered into as of February 4, 2004 by and between The Institute for Systems Biology (the “Institute”), a Washington nonprofit corporation, having its principal place of business at 1441
No. 34th Street, Seattle, WA 98103, and NanoString Technologies, Inc, (“Licensee”), and shall be effective upon satisfaction of Licensee’s obligations pursuant to Sections 4.1 and 6.2 of this Agreement (the
“Effective Date”). 
 RECITALS 
 WHEREAS, the Institute is the owner of the Licensed Patents and Licensed Know-How (as defined below); 
 WHEREAS, the Institute is willing to grant an exclusive license under the Licensed Patents and Licensed Know-How to Licensee on the terms, and subject to the conditions, set forth herein; and 

WHEREAS. Licensee desires to obtain an exclusive license under the Licensed Patents and Licensed Know-How from the Institute. 

NOW, THEREFORE, for and in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereby expressly agree as follows: 
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 Nanostring Exclusive License Agreement 
  Page
 2
 of 25 
  

 AGREEMENT 

 

	1.	DEFINITIONS AS USED HEREIN 

  

	1.1	“Licensed Patents” means the patent applications listed on Appendix A and any patent applications filed by Institute or Licensee claiming
Licensed Know-How, the inventions described and claimed therein and any divisionals, continuations, continuations-in-part, but only to the extent that such continuation-in-part applications are directed to subject matter specifically described in
and can claim benefit of the priority of a patent application(s) listed on Appendix A, extensions (including supplemental protection certificates), substitutions, registrations, confirmations, re-examinations, renewals and patents issuing thereon or
reissues thereof: and any and all foreign patents and patent applications corresponding thereto, which are owned by or under the control of the Institute, and which will be automatically added to Appendix A 

 

	1.2	“End User” means any user who exploits the utility of a Licensed Product. 

 

	1.3	“Field” means all diagnostic and therapeutic uses. 

 

	1.4	“Licensed Product(s)” means any method, composition, or device the manufacture, use, sale, offer for sale, or import of which, but for the
license granted in this Agreement, would infringe or contribute to the infringement of a Valid Claim. 

  

	1.5	“Licensed Know-How” shall mean any and all technical information, processes, compositions, formulae, data, engineering, materials, reports,
analyses, know-how, trade secrets and other subject matter (i) owned by, or subject to an obligation to assign to, the Institute; and (ii) necessary or useful for the development, manufacture, use and/or commercialization of the Licensed
Products in the Field; and (iii) documented in the laboratory notebooks identified on Appendix B. 

  

	1.6	“Net Sales” shall mean LICENSEE’s and its sublicensees’ billings for LICENSED PRODUCTS produced hereunder less the sum of the
following: 

  

	 	(a)	discounts allowed in amounts customary in the trade; 

  

	 	(b)	sales, tariff duties and/or use taxes directly imposed and with reference to particular sales; 

 

	 	(c)	outbound transportation prepaid or allowed; and 

  

	 	(d)	amounts allowed or credited on returns. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -2- 

 Nanostring Exclusive License Agreement 
  Page
 3
 of 25 
  

 No deductions shall be made for commissions paid to individuals whether they be with
independent sales agencies or regularly employed by LICENSEE and on its payroll, or for cost of collections. LICENSED PRODUCTS shall be considered “sold” when billed out or invoiced. 

 

	1.7	“Affiliates” means any corporation, partnership, joint venture or other entity of which fifty percent (50%) or more of the common stock or
other equity ownership thereof is owned by Licensee or which owns fifty percent (50%) or more of the common stock or other equity ownership of Licensee. 

 

	1.8	“Effective Date” is as defined in the initial paragraph of this Agreement. 

 

	1.9	“Parties” means Licensee and the Institute. 

  

	1.10	“First Commercial Sale” means the first sale to an End User of a Licensed Product; provided, however, that a sale to an Affiliate will
not constitute a First Commercial Sale unless the Affiliate is an End User. 

  

	1.11	“Valid Claim” means a claim of (a) a pending patent application included within the Licensed Patents, which claim, together with any
amended versions thereof, has not been pending for longer than five years after the First Commercial Sale of a Licensed Product; or (b) an issued patent included within the Licensed Patents, which claim has not lapsed, been canceled or
became abandoned and has not been declared invalid or unenforceable by an unreversed and unappealable decision or judgment of a court or other appropriate body of competent jurisdiction, and which has not been admitted to be invalid or unenforceable
through reissue, disclaimer or otherwise. 

  

	1.12	“Commercially Reasonable Efforts” means the efforts that a reputable pharmaceutical or biotechnology company would use to develop and
commercialize in a commercially and scientifically reasonable and diligent manner, one of such company’s principal technologies or products, giving full consideration to all relevant matters, such as science, costs, regulatory approvals and
market conditions. 

  

	2.	GRANT OF LICENSE 

  

	2.1	 License Grant. The Institute grants to Licensee an exclusive, worldwide license under the Licensed Patents and Licensed Know-How, and within
the Field to make, have made, use, sell, offer for sale or import Licensed Products, including the 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -3- 

 Nanostring Exclusive License Agreement 
  Page
 4
 of 25 
  

	 	
right to grant sublicenses pursuant to Section 2.2. This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of the
Institute other than Licensed Patents regardless of whether such patents are dominant or subordinate to Licensed Patents. 

  

	2.2	Sublicensing. 

  

	 	(a)	For so long as Licensee is in compliance with its obligations under this Agreement, Licensee may grant sublicenses under the Licensed Patents and Licensed Know-How to
the extent of the rights granted to Licensee in Section 2.1. 

  

	 	(b)	Licensee will not grant any rights that are inconsistent with the rights granted to and obligations imposed on Licensee hereunder. No such sublicense agreement will
contain any provision that would cause it to extend the term of this Agreement or increase in any way any Institute’s obligations under this Agreement. 

 

	 	(c)	Licensee will be responsible for its sublicensees’ compliance with the terms of this Agreement. Any act or omission of a sublicensee which would be a breach of
this Agreement if performed by the Licensee will deemed to be a breach by Licensee of this Agreement. 

  

	 	(d)	Licensee agrees to provide the Institute with a copy of each sublicense within thirty days of its full execution provided that Licensee shall have the right to redact
any information that is not relevant to the Licensed Patents or Licensee’s obligations hereunder. Each sublicense shall comply with the requirements of this Section 2.2. 

 

	 	(e)	Upon termination of this Agreement for any reason, any sublicense not then in default shall continue in full force and effect except that the Institute shall be
substituted in place of Licensee; provided that, within sixty (60) days of such termination, each sublicensee agrees in writing to be bound by all the applicable terms and conditions of this Agreement. Licensee shall notify the sublicensees of
any such termination within thirty (30) days of such termination. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -4- 

 Nanostring Exclusive License Agreement 
  Page
 5
 of 25 
  

	2.3	Reserved Rights. The license grant set forth in Section 2.1 will be further subject to, restricted by and non-exclusive with respect to:

  

	 	(a)	the use of Inventions described or claimed in the Licensed Patents and Licensed Know-How by the Institute solely for non-commercial research, teaching and other
educational purposes; 

  

	 	(b)	subject to the prior written consent of Licensee and appropriate confidentiality and limited use restrictions, the use of inventions described or claimed in the
Licensed Patents and Licensed Know-How by the Institute’s collaborators at academic or research institutions solely for non-commercial research purposes; 

 

	 	(c)	any non-exclusive license of inventions described or claimed in the Licensed Patents and Licensed Know-How that the Institute is required by law or regulation to grant
to the United States of America or to a foreign state pursuant to an existing or future treaty with the United States of America; and 

  

	 	(d)	any rights not included within the Field. 

  

	2.4	Licensee agrees that, where required by government law or regulation, products used or sold in the United States embodying Licensed Products shall be
manufactured substantially in the United States, unless a written waiver is obtained in advance from the United States Government. 

  

	3.	LICENSED PRODUCT DEVELOPMENT EFFORTS 

  

	3.1	Commercially Reasonable Efforts. Licensee will at all times use Commercially Reasonable Efforts to: 

Realize Net Sales to End Users of at least $[†] for one or more Licensed Products on or before the [†] ([†]) anniversary of
this Agreement or pay a minimum annual royalty payment of $[†] per year, with the first such payment due on the [†] anniversary of the Effective Date (“Milestone Event”). 

Upon the First Commercial Sale, thereafter and until the expiration of this Agreement, Licensee shall use Its Commercially Reasonable
Efforts to keep Licensed Products reasonably accessible to the public. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -5- 

 Nanostring Exclusive License Agreement 
  Page
 6
 of 25 
  

	3.2	Institute’s Remedy. If Licensee is not using Commercially Reasonable Efforts to achieve a particular Milestone Event, by the time specified in
Section 3.1, then Institute may, subject to Licensee’s right to contest under Section 3.3, terminate this Agreement. 

  

	3.3	Licensee’s Remedies. If the Institute elects to terminate this Agreement as specified in Section 3.2 and Licensee contests such election, then prior to
the Institute taking such remedy: 

  

	 	(a)	The Institute shall provide written notice of its intention to terminate this Agreement pursuant to Section 3.2. As soon as practicable after receipt of such
notice and in any event no later than ten (10) business days thereafter, the President of Licensee and a designated officer with appropriate settlement authority from the Institute shall meet at a mutually agreed upon time and location for the
purpose of discussing the basis of the Institute’s decision to terminate. They shall engage in good faith discussions and/or negotiations for a period of up to ten (10) days to resolve the disagreement or negotiate an interpretation or
revision of the applicable portion of this Agreement which is mutually agreeable to both parties, without the necessity of formal procedures relating thereto. During the course of such discussion and/or negotiation, the parties shall reasonably
cooperate and provide information that is not materially confidential in order so that each of the parties may be fully informed with respect to the issues in dispute. 

 

	 	(b)	In the event the parties do not reach agreement pursuant to Section 3.3(a), Licensee may request, and Institute will agree to submit to binding arbitration, the
question of whether or not Licensee has used Commercially Reasonable Efforts to satisfy a particular Milestone Event. Such dispute will be submitted to final and binding arbitration under the then current commercial rules and regulations of the
American Arbitration Association (“AAA”) relating to voluntary arbitrations. The arbitration proceedings will be held in Seattle, Washington. The arbitration will be conducted by one arbitrator, who is knowledgeable in the subject
matter at issue in the dispute and who will be selected by mutual agreement of the Parties or failing such agreement, will be selected in accordance with the AAA rules. The decision of the arbitrator will be final and binding on the Parties.

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -6- 

 Nanostring Exclusive License Agreement 
  Page
 7
 of 25 
  

	 	(c)	If the arbitrator in said arbitration finds that Licensee has used Commercially Reasonable Efforts or satisfied the Milestone Event at issue, the Agreement will not be
terminated. 

  

	 	(d)	If the arbitrator in said arbitration finds that Licensee has not used Commercially Reasonable Efforts or has failed to satisfy the Milestone Event at issue, the
Institute may terminate this Agreement as specified in Section 3.2 above. 

  

	 	(e)	If Licensee (or its sublicensees) achieves any Milestone Event set forth in Section 3.1, then that constitutes conclusive evidence that Licensee has used
Commercially Reasonable Efforts with respect to such Milestone Event. If Institute attempts to pursue a remedy pursuant to Section 3.2 (which is contested by Licensee pursuant to Section 3.3) because Institute believes that Licensee is not
using Commercially Reasonable Efforts to meet a Milestone Event, but the time period specified for the applicable Milestone Event has not yet elapsed, then the burden of proof will be on Institute to prove that Licensee has not used Commercially
Reasonable Efforts. Alternatively, if Institute attempts to pursue a remedy pursuant to Section 3.2 (which is contested by Licensee pursuant to Section 3.3) because Licensee has failed to meet a Milestone Event within the time period
specified, and the time period for such Milestone Event has already elapsed, then the burden of proof will be on Licensee to prove that Licensee has used Commercially Reasonable Efforts to achieve such Milestone Event but despite such Commercially
Reasonable Efforts, Licensee was unable to do so. 

  

	4.	PAYMENTS AND REPORTS 

  

	4.1	License Fee. As partial consideration for the license granted herein, Licensee shall issue to Institute shares of Common Stock of Licensee representing [†]
percent ([†]%) of the outstanding capital stock issued to all founders, including the Institute, prior to the first closing of Licensee’s Series A Preferred Stock financing (the “Initial Closing”).

  

	4.2	Royalties. Licensee will pay Institute a royalty equal to [†]% of Net Sales Licensed Products made by Licensee and/or its Sublicensees.

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -7- 

 Nanostring Exclusive License Agreement 
  Page
 8
 of 25 
  

	4.3	Combination Products. If a Licensed Product is sold in conjunction with or includes other components that contribute value to said Licensed Product
(“Combination Licensed Product”), then in lieu of the royalty rate specified in Section 4.2 of the Agreement, the applicable royalty rate on the Net Sales of such Combination Licensed Product will be calculated as the product
obtained by multiplying the royally specified in Section 4.2 by the fraction A/(A+B), in which A is the value of the technology licensed under this Agreement and B is the value of the other components; provided, however, that in no event will
the royalty rate payable to the Institute be less than [†] percent ([†]%) of the royalty specified in Section 4.2. For purposes of this Section the “value” of each component contributing value to the Licensed Product shall
mean that component’s contribution to the combined value of the Combination Licensed Product. The value of A and B will be determined in good faith by Institute and Licensee. As of the Effective Date A/(A+B)=1. 

 

	4.5	Sales to Affiliates. In order to assure Institute the full royalty payments on Net Sales contemplated in this Agreement, Licensee agrees that in the event any
Licensed Product is sold for purposes of resale to an Affiliate, then the royalties to be paid in respect to such Licensed Product will be computed on the net selling price at which the Affiliate sells such Licensed Products, rather than on the net
selling price of Licensee. The calculation of the net selling price on which the royalties under this paragraph will be paid will be determined in the some manner as Net Sales. 

 

	4.6	One Royalty. For the avoidance of doubt, it is understood that no more than one royalty payment shall be due with respect to the sale of a particular Licensed
Product. The obligation to pay royalties to Institute is imposed only once with respect to the same unit of Licensed Product regardless of the number of Valid Claims pertaining thereto. 

 

	4.7	 Payments. Licensee will make payments to the Institute specified in Sections 4.2 within [†] ([†]) days after
March 31, June 30, September 30 and December 31 of each year during the term of this Agreement covering the quantity of Licensed Products sold by Licensee during the preceding calendar quarter. After termination or
expiration of this Agreement, Licensee will make a final payment covering the final whole or partial calendar quarter. A written statement of Net Sales of Licensed Products by Licensee, Affiliates or sublicensees during such calendar quarter will
accompany each quarterly payment. Such written statements will be duly signed and certified by an authorized signatory of Licensee on behalf of Licensee and will 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -8- 

 Nanostring Exclusive License Agreement 
  Page
 9
 of 25 
  

	 	
show the Net Sales of Licensed Products by Licensee, Affiliates or sublicensees during such calendar quarter and the amount of royalties payable under this Agreement based thereon.

  

	4.8	Form of Payment. All payments due hereunder are expressed in and will be paid by wire transfer or check payable in U.S. dollars, without deduction of
exchange, collection or other charges, to the Institute, or to the account of the Institute at such other bank as the Institute may from time to time designate by written notice to Licensee. 

 

	4.9	Interest. In the event that any payment due hereunder is not made when due, the payment will accrue interest beginning on the tenth day following the due date
thereof, calculated at the annual rate of the sum of (a) two percent (2%) plus (b) the prime interest rate quoted by The Wall Street Journal on the date said payment is due, the interest being compounded on the last day of each
calendar quarter; provided, however, that in no event will said annual interest rate exceed the maximum legal interest rate for corporations. Each such royalty payment when made will be accompanied by all interest so accrued. Said interest and the
payment and acceptance thereof will not negate or waive the right of the Institute to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment. 

 

	4.10	Exchange Rate. Whenever conversion of payments from any foreign currency to U.S. dollars is required, such conversion will be made at the rate of exchange
reported in the Wall Street Journal on the last business day of the applicable reporting period. 

  

	5.	RECORDS AND INSPECTION 

Licensee will maintain or cause to be maintained a true and correct set of records pertaining to the activities contemplated under this
Agreement for a period of [†] ([†]) years following a given reporting period, including Net Sales of Licensed Products by Licensee, Affiliates and sublicensees under this Agreement. Licensee agrees to permit an independent certified public
accountant selected and paid by the Institute and reasonably acceptable to Licensee to have access during ordinary business hours to such records, including, but not limited to, complete copies of sublicense agreements, as are maintained by Licensee
and as may be necessary, in the opinion of such accountant, to determine the correctness of any report and/or 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -9- 

 Nanostring Exclusive License Agreement 
  Page
 10
 of 25 
  

 payment made under this Agreement. Such audits may be exercised no more than once in any
[†] ([†]) month period upon at least [†] ([†]) days prior written notice to Licensee. The Institute will bear the full cost of such audit unless the audit reveals an underpayment of royalty by more than [†] percent
([†]%). In such case, Licensee will pay the cost of the audit. Such accountant will maintain in confidence, and will not disclose to the Institute, any information concerning Licensee or its operations or properties other than information
directly relating to the correctness of such reports and payments. 
  

	6.	PATENTS 

  

	6.1	Patent Prosecution and Maintenance. From and after the Effective Date of this Agreement, the provisions of this Section 6 will control the filing,
prosecution and maintenance of the Licensed Patents. Licensee will direct and manage (i) the preparation, filing and prosecution of the United States and foreign patent applications arising from or relating to the Licensed Patents (including
any interferences and foreign oppositions) and (ii) the maintenance of the Licensed Patents. The Institute will select the patent attorney, subject to Licensee’s prior written approval, which approval will not be unreasonably withheld and
the Institute will be said attorney’s client. The Institute and Licensee will consult from time to time on patent matters, at which time patent counsel may be changed by mutual agreement of the parties. 

 

	6.2	Patent Costs. Licensee will reimburse Institute for all reasonable and necessary out-of-pocket patent expenses incurred by Institute prior to the Effective Date
incident to the filing, prosecution and maintenance of the Licensed Patents. After the Effective Date Licensee will be responsible to pay all costs incurred incident to filing, prosecution and maintenance of the Licensed Patents directly to the
patent attorney within thirty (30) days after Licensee receives an invoice therefore. 

  

	6.3	 Effect of Licensee’s Abandonment. In the event that Licensee decides not to continue to the prosecution of a patent application or patent
within the Licensed Patents in a particular country, Licensee will give Institute at least [†] ([†]) days prior written notice of such election. No such decision will have any effect on Licensee’s obligations to pay expenses incurred
up to the effective date of such election. From and after the effective date of such election, Institute will have the right, but not the obligation, to assume, at its own expense, the prosecution and/or maintenance of the patent application or
patent which Licensee is discontinuing in the applicable 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -10- 

 Nanostring Exclusive License Agreement 
  Page
 11
 of 25 
  

	 	
country. From and after the effective date of such election, solely with respect to the applicable country, any such patent application or patent as to which Licensee will have elected to
discontinue will thereafter be excluded from Licensed Patents and from the scope of the license granted under this Agreement. All rights relating to such patent application or patent in such country will revert to Institute and may be freely
licensed by Institute to any other person or entity. 

  

	6.4	Information to Institute. Licensee will use good faith efforts to first consult with the Institute as to the preparation, filing, prosecution and maintenance of
all the Licensed Patents. Licensee shall furnish to the Institute copies of all material documents relevant to any such preparation, prosecution and maintenance of any patent covering Licensed Patents. Without limiting the foregoing, Licensee will
submit to Institute copies of all patent applications, official actions and responses thereto. 

  

	6.5	Cooperation. Institute and Licensee will cooperate fully in the preparation, filing, prosecution and maintenance of Licensed Patents and Licensed Know-How,
executing all papers and instruments or requiring members of Institute to execute such papers and instruments so as to enable Institute to apply for, to prosecute and to maintain patent applications and patents in Institute’s name in any
country. Each Party shall provide to the other prompt notice as to all matters which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any such patent applications or patents. 

 

	6.6	Infringement. While and as long as its license under this Agreement remains exclusive, Licensee is empowered to take the following actions, provided that
Licensee gives at least [†] ([†]) [†] days prior written notice to the Institute of its intent to take any such actions and considers the Institute’s views and public interest with respect to the consequences of such actions:

  

	 	(a)	Bring suit in its own name, or if required by law, jointly with Institute, for infringement of the Licensed Patents, provided, however, that Licensee uses counsel
experienced in prosecuting such suits. If License brings suit and Institute is required to be added by law, the cost of Institute’s participation will be paid by Licensee.; 

 

	 	(b)	In any such suit to enjoin infringement and to collect for its use, damages, profits, and awards of whatever nature recoverable for such infringement; and

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -11- 

 Nanostring Exclusive License Agreement 
  Page
 12
 of 25 
  

	 	(c)	To settle any claim or suit for infringement or violation of the Licensed Patents by granting the infringing party a sublicense pursuant to the provisions of
Article 2 of this Agreement. 

 If Institute brings to the attention of Licensee in writing any unlicensed
infringement of the Licensed Patents within the Field, and Licensee does not, within [†] ([†]) months after Licensee’s receipt of such notice; 
  

	 	(x)	Secure cessation of the infringement; 

  

	 	(y)	File suit against the infringer; or 

  

	 	(z)	Provide Institute with evidence of the pendency of a bona fide negotiation for the acceptance by the infringer of a sublicense pursuant to the provisions of Article
2 of this Agreement; 

 then the Institute shall thereafter have the right to sue for the infringement
at Institute’s own expense, and to collect for its own use all damages, profits, and awards of whatever nature recoverable for such infringement. 
 Notwithstanding the foregoing, Institute shall have the option, in its sole discretion and at its own expense, to voluntarily participate in any suit, including any declaratory judgment action, brought
by or against Licensee concerning the Licensed Patents, and in such case, any recovery obtained shall be split in proportion to the amount of litigation fees incurred by each Party. Licensee shall keep the Institute fully informed of any action or
proceeding brought by or against Licensee concerning the Licensed Patents. The Parties agree to render each other such assistance as they may reasonably require of each other and to cooperate in good faith with each other to ensure the proper and
adequate defense or prosecution of any action or proceeding brought by or against any third party relating to the Licensed Patents. 
  

	6.7	Settlement of Infringement Actions. Neither Party may settle any infringement action covered by Section 6.6 in a manner that diminishes the rights or
interests of the other Party without first obtaining the prior written consent of such other Party. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -12- 

 Nanostring Exclusive License Agreement 
  Page
 13
 of 25 
  

	6.8	Liability for Loss. The Institute will not be liable for any losses incurred as the result of an action for infringement brought against Licensee as the result
of Licensee’s exercise of any right granted under this Agreement. 

  

	7.	TERM AND TERMINATION 

  

	7.1	Termination. Unless earlier terminated as hereinafter provided, this Agreement will extend for the life of the last to expire patent issued on the Licensed
Patents and will then expire automatically, or if no patent issues on the Licensed Patents, this Agreement will continue in full force and effect for a period of five (5) years from the First Commercial Sale of Licensed Products. After such
five year period, Licensee will have a license on the same terms as set forth in Section 2.1, except that the license will be a royally-free license and Licensee shall not be obligated to make any payments with respect to Net Sales until such
time as one or more patents issues on the Licensed Patents. Upon issuance of any such patent payments related to that patent will once again be payable by Licensee from the date of that patent’s issuance in accordance with the rates and the
terms and conditions set forth herein. 

  

	7.2	Default remedies. 

  

	 	(a)	If Licensee at any time defaults in the payment of any sum due after the Effective Date when due hereunder and fails to make such payment within fifteen (15) days
after receipt of written notice thereof by Institute, Institute may, at its option, terminate this Agreement and all licenses granted herein by notice in writing to such effect. 

 

	 	(b)	If either Party at any time materially defaults in the making of any report hereunder, or commits any material breach of any of the terms, covenants or provisions of
this Agreement, or makes any materially false report and fails to remedy any such default, breach or report within thirty (30) days after receipt of written notice thereof by the non-breaching Party, the non-breaching Party may, at its option,
terminate this Agreement after an additional 30 day cure period to remedy the breach or default by notice in writing to such effect but only if the non-breaching Party first complies with the terms of Section 7.2(c) below. Termination will be
effective within five (5) business days of the date of receipt by breaching Party of the notice of termination. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -13- 

 Nanostring Exclusive License Agreement 
  Page
 14
 of 25 
  

	 	(c)	Any dispute under this Agreement other than a dispute arising from a breach of confidentiality, infringement of intellectual property rights or the failure to pay any
amount that is readily determinable pursuant to the terms of this Agreement, shall be resolved in accordance with the following procedure: 

  

	 	(i)	Either Party may at any time provide the other Party written notice specifying the terms of such disagreement in reasonable detail. As soon as practicable after receipt
of such notice, the President of Licensee and a designated officer with appropriate settlement authority from the Institute shall meet at a mutually agreed upon time and location for the purpose of resolving the dispute. They shall engage in good
faith discussions and/or negotiations for a period of up to ten (10) days to resolve the disagreement or negotiate an interpretation or revision of the applicable portion of this Agreement which is mutually agreeable to both Parties, without
the necessity of formal procedures relating thereto. During the course of such discussion and/or negotiation, the parties shall reasonable cooperate and provide information that is not materially confidential in order so that each of the Parties may
be fully informed with respect to the issues in dispute. 

  

	 	(ii)	In the event the Parties do not reach agreement pursuant to Section 7.2(c)(i), the aggrieved Party shall request and the other Party will agree to submit to
binding arbitration, the question of whether or not this Agreement has been breached. Such dispute will be submitted to final and binding arbitration under the then current commercial rules and regulations of the AAA relating to voluntary
arbitrations. The arbitration proceedings will be held in Seattle, Washington. One arbitrator, who is knowledgeable in the subject matter at issue in the dispute and who will be selected by mutual agreement of the Parties or failing such agreement,
will be selected in accordance with the AAA rules and will conduct the arbitration. The decision of the arbitrator will be final and binding on the Parties. 

 

	 	(iii)	If the arbitrator in said arbitration finds that a Party has materially breached this Agreement, then, and only then, the other Party may terminate this Agreement as
specified in Section 7.2(b) above. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -14- 

 Nanostring Exclusive License Agreement 
  Page
 15
 of 25 
  

	7.3	Default for bankruptcy. Each Party will have the right, at its option, to cancel and terminate this Agreement in the event that the other Party (i) becomes
involved in insolvency, dissolution, bankruptcy or receivership proceedings affecting the operation of its business (other than dissolution or winding up for the purposes of reconstruction or amalgamation) or (ii) makes an assignment of all or
substantially all of its assets for the benefit of creditors, or in the event that (iii) a receiver or trustee is appointed for the other Party and such Party will, after the expiration of thirty (30) days following any of the events
enumerated above, be unable to secure a dismissal, stay or other suspension of such proceedings. In the event of termination of this Agreement under this Section 7.3, all rights to the Licensed Patents will revert to the Institute.

  

	7.4	Rights after termination. At the date of any termination of this Agreement pursuant to Section 7.2 hereof for material breach by Licensee, or pursuant to
Section 7.3 hereof In the event of bankruptcy by Licensee, as of the receipt by Licensee of notice of such termination, Licensee will immediately cease using any of the Licensed Patents and return all copies of the same to the Institute;
provided, however, that Licensee may for six (6) months dispose of any Licensed Products actually in the possession of Licensee or as to which it has made irrevocable commitments to sell or have made prior to the date of termination, subject to
Licensee’s paying to the Institute running royalties in accordance with Section 4.2 with respect thereto and otherwise complying with the terms of this Agreement. 

 

	7.5	No waiver. No termination of this Agreement will constitute a termination or a waiver of any rights of either Party against the other Party accruing at or prior
to the time of such termination. The obligations and rights of the Parties under Section 5 will survive termination of this Agreement. 

  

	8.	ASSIGNABILITY 

 The rights
and licenses granted by Institute in this Agreement are personal to Licensee and may not be assigned or otherwise transferred without the written consent of Institute (such consent not to be unreasonably withheld); provided however that Licensee
may, without such consent but with notification, assign this Agreement and its rights and obligations hereunder to any of its Affiliates, or in connection with the transfer or sale of all or substantially all of its business or its merger,
acquisition or other consolidation with or into another party other than a transfer or sale in connection with Licensee’s insolvency, dissolution, bankruptcy or 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -15- 

 Nanostring Exclusive License Agreement 
  Page
 16
 of 25 
  

 receivership proceedings. Any permitted assignee shall assume all rights and obligations
of its assignor under this Agreement. Any attempted assignment or transfer without consent under circumstances requiring the Institute’s consent shall be void and shall automatically terminate all rights of Licensee under this Agreement.

  

	9.	GOVERNMENTAL COMPLIANCE 

Licensee will, at all times during the term of this Agreement and for so long as it sells Licensed Products, comply and require its
sublicensees to comply with all laws that control the import, export, manufacture, use, sale, marketing, distribution and other commercial exploitation of Licensed Products or any other activity undertaken pursuant to this Agreement. 

 

	10.	GOVERNING LAW 

 This
Agreement will be governed by, and will be construed and enforced in accordance with, the laws of the State of Washington. This Agreement is expressly acknowledged to be subject to all federal laws, including, but not limited to, the Export
Administration Act of the United States of America. No conflict-of-laws rule or law that might refer such construction and interpretation to the laws of another state, republic or country will be considered. 

 

	11.	ADDRESSES 

 Any payment, notice or other
communication pursuant to this Agreement will be mailed by first class, certified or registered mail, postage prepaid, or delivered by overnight delivery service addressed as follows or to such other address designated by written notice given to the
other Party: 
 In the case of the Institute: 
 Vice President - COO 
 The Institute for Systems Biology 

1441 No. 34th Street 
 Seattle, WA 98103 
 In the case of Licensee: 

President 

NanoString Technologies, Inc. 
 c/o Heller Ehrman Venture Law Group 
 701 Fifth Ave., Suite 6100 

Seattle, WA 98104 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -16- 

 Nanostring Exclusive License Agreement 
  Page
 17
 of 25 
  

 Any such payment, notice or other communication will be effective upon receipt.

  

	12.	ADDITIONAL PROVISIONS 

  

	12.1	Use of the Institute’s Name. Licensee agrees that it will not use in any way the name “The Institute for Systems Biology” or any logotypes or
symbols associated with the Institute or the names of any of the Institute’s faculty members, scientists, researchers, employees, officers, trustees, directors, or agents without the prior written consent of the Institute except
as necessary to comply with law, as a result of judicial process, or as is customary in financing, licensing, corporate partnering and strategic alliance transactions. 

 

	12.2	Confidentiality. Each Party agrees to maintain the Confidential Information (defined below) of the other Party in confidence, and to use the same only in
accordance with the terms of this Agreement. 

 For purposes of this Agreement, “Confidential
Information” means any information that is disclosed by either Party to the other in connection with this Agreement and which is specifically designated as confidential in writing, or if disclosed orally is confirmed in writing as being
confidential within thirty (30) days of disclosure, except that the receiving Party will have no obligation of confidentiality with respect to any information designated as confidential by the disclosing Party that is: 

 

	 	(a)	Known to the receiving Party at the time of disclosure thereof, as demonstrated by documentary evidence; or 

 

	 	(b)	At the time of disclosure, or thereafter, generally publicly available without the fault of the receiving Party; or 

 

	 	(c)	Subsequently disclosed to the receiving Party, its employees, or other duly designated representatives, by any third party not under a secrecy obligation to the
disclosing Party; 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -17- 

 Nanostring Exclusive License Agreement 
  Page
 18
 of 25 
  

	 	(d)	Independently developed by the receiving Party without reference to Confidential Information of the disclosing Party, as demonstrated by documentary evidence;

  

	 	(e)	Required, by law, regulation or action of any governmental agency or authority, to be disclosed, provided that the receiving Party shall provide reasonable advance
notice to enable the disclosing Party to seek a protective order or otherwise prevent such disclosure; or 

  

	 	(f)	Disclosed by the receiving Party with the prior written consent of the disclosing Party. 

Each Party (a) shall treat as confidential all Confidential Information provided by the other Party, (b) shall not use such
Confidential Information except as expressly permitted under the terms of this Agreement or otherwise authorized in writing by the disclosing Party, (c) shall implement reasonable procedures to prohibit the disclosure, unauthorized duplication,
misuse or removal of such Confidential Information by its employees, agents, representatives, contractors or consultants, and (d) shall not disclose such Confidential Information to any Third Party except as may be expressly allowed under this
Agreement. Without limiting the foregoing, each of the Parties shall use at least the same procedures and the highest degree of care to prevent the disclosure of Confidential Information as it uses to prevent the disclosure of its own confidential
information of like importance, and shall in any event use no less than reasonable procedures and a reasonable degree of care. The foregoing obligation of confidentiality will survive for a period of five (5) years following the termination of
this Agreement. Each Party will promptly notify the other Party upon discovery of any unauthorized use of disclosure of the other Party’s Confidential Information. 
 The Parties agree that due to the unique nature of the Confidential Information, there can be no adequate remedy at law for any breach of the receiving Party’s obligations under this Agreement,
thereby resulting in irreparable harm to the disclosing party. Therefore, notwithstanding Section 7.2(c) hereof, upon any such breach of this Section 12.2 or any threat thereof, the disclosing Party shall be entitled to seek appropriate
mandatory or negative injunctive relief. 
 Notwithstanding anything in this Agreement or in any other written or oral
understanding or agreement to which the Parties hereto are parties or by which they 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -18- 

 Nanostring Exclusive License Agreement 
  Page
 19
 of 25 
  

 are bound, each Party (and its representatives, agents and employees) may consult any
tax advisor regarding the tax treatment and tax structure of the transaction contemplated by this Agreement and may at any time disclose to any person, without limitation of any kind, the tax treatment and tax structure of such transaction and all
materials (including opinions or other tax analyses) that are provided relating to such treatment or structure. The preceding sentence is intended to satisfy the requirements for the transaction contemplated herein to avoid classification as a
“confidential transaction” in accordance with Treasury Regulations Section 1.6011-4(b)(3) and shall be interpreted consistent with such intent. 
  

	12.3	Indemnity. Licensee will defend, indemnify and hold Institute harmless against all liabilities, demands, damages, expenses (including reasonable
attorneys’ fees and costs), or losses in connection with any claims, suits, actions, demands or judgments arising out of any theory of liability (including, without limitation, actions in the form of tort, warranty, or product liability,
and regardless of whether such action has any factual basis) concerning (1) any product, process or service that is made, used, sold, offered for sale, imported, performed or otherwise disposed pursuant to any right or license granted under
this Agreement, and (2) the negligent acts or omissions or willful misconduct of Licensee, sublicensees, or customers, employees or agents of the foregoing. 

 

	12.4	Insurance. Licensee will for so long as Licensee manufactures, uses or sells any Licensed Product(s), maintain in full force and effect policies of
(i) worker’s compensation and/or employers’ liability insurance within statutory limits, (ii) general liability insurance (with broad form general liability endorsement) with limits of not less than one million dollars
($1,000,000) per occurrence and a $2,000,000 annual aggregate and (iii) occurrence basis, products liability insurance, with limits of not less than five million dollars ($5,000,000) per occurrence and a $5,000,000 annual aggregate, provided
that such policy shall be obtained no later than thirty (30) days prior to delivery of a Licensed Product to a third-party customer. Such coverage(s) will be purchased from a carrier or carriers deemed reasonably acceptable to the Institute
with no annual aggregate and will name the Institute as an additional insured. Upon request by the Institute, Licensee will provide to the Institute copies of said policies of insurance. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -19- 

 Nanostring Exclusive License Agreement 
  Page
 20
 of 25 
  

	12.5	The Institute’s Disclaimers. Neither the Institute, nor any of its faculty members, researchers, trustees, officers, employees, directors, or agents assumes
any responsibility for the manufacture, sale or use of the Licensed Products. 

  

	12.6	Independent Contractors. The Parties hereby acknowledge and agree that each is an independent contractor and that neither Party wit be considered to be the
agent, representative, master or servant of the other Party for any purpose whatsoever, and that neither Party has any authority to enter into a contract, to assume any obligation or to give warranties or representations on behalf of the other Party
without the prior written consent of the other Party. Nothing in this relationship will be construed to create a joint venture, agency, partnership, fiduciary or other similar relationship between the Parties. 

 

	12.7	Corporate Power. Each Party hereby represents and warrants that such Party is duly organized and validly existing under the laws of the state of its
incorporation and has full corporate authority to enter into this Agreement and to carry out the provisions hereof. 

  

	12.8	Due Authorization/Ownership/No Suit/Validity. Each Party hereby represents and warrants that such Party is duly authorized to execute and deliver this Agreement
and to perform its obligations hereunder. Except for the rights, if any, of the Government of the United States, the Institute represents that, to the best of its current knowledge (without investigation outside of the Institute as to such
representations), (a) it is the sole owner of the Licensed Patents, (b) and that all applicable assignments have been recorded, and (c) no action, suit or claim has been initiated or threatened with respect to the Licensed Patents.

  

	12.9	Binding Obligation. Each Party hereby represents and warrants that this Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms. The execution, delivery and performance of this Agreement by such Party does not conflict with any license, agreement, instrument, or understanding, oral or written, to which it is a party or by which it may be bound, nor
violate any law or regulation or any court, government body or administrative or other agency having authority over it. 

  

	12.10	 DISCLAIMER OF WARRANTY. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, INSTITUTE MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EXPRESSED
OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -20- 

 Nanostring Exclusive License Agreement 
  Page
 21
 of 25 
  

	 	
WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OR MERCHANTABILITY. IN ADDITION TO AND NOT TO LIMIT THE FOREGOING, INSTITUTE SHALL HAVE NO LIABILITY FOR, AND INSTITUTE
MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND REGARDING THE PATENTABILITY, VALIDITY AND/OR SCOPE OF THE LICENSED PATENTS (IN WHOLE OR IN PART) OR OF THE ENFORCEABILITY OF ANY PATENTS ISSUING THEREUPON, IF ANY, OR THAT THE
LICENSED PATENTS OR LICENSED PRODUCTS ARE OR WILL BE FREE FROM INFRINGEMENT OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF INSTITUTE OR OF THIRD PARTIES. 

 

	12.11	Limitation of Liability. Neither Party will be entitled to recover from the other Party any special, incidental, exemplary, consequential or punitive damages in
connection with this Agreement or any license granted hereunder. 

  

	12.12	Non-Waiver. The Parties covenant and agree that if a Party fails or neglects for any reason to take advantage of any of the terms provided for the termination of
this Agreement or if a Party, having the right to declare this Agreement terminated, will fail to do so, any such failure or neglect by such Party will not be a waiver or be deemed or be construed to be a waiver of any cause for the termination of
this Agreement subsequently arising, or as a waiver of any of the terms, covenants or conditions of this Agreement or of the performance thereof. None of the terms, covenants and conditions of this Agreement may be waived by a Party except by its
written consent. 

  

	12.13	Reformation. The Parties hereby agree that neither Party will violate any public policy, statutory or common law, rule, regulation, treaty or decision of any
government agency or executive body thereof of any country or community or association of countries applicable to this Agreement; that if any word, sentence, paragraph or clause or combination thereof of this Agreement is found, by a court or
executive body with judicial powers having jurisdiction over this Agreement or any of its Parties hereto, in a final unappealed order to be in violation of any such provision in any country or community or association of countries, such words,
sentences, paragraphs or clauses or combination will be inoperative in such country or community or association of countries, and the remainder of this Agreement will remain binding upon the Parties hereto. 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -21- 

 Nanostring Exclusive License Agreement 
  Page
 22
 of 25 
  

	12.14	Force Majeure. No liability hereunder will result to a Party by reason of delay in performance caused by force majeure that is circumstances beyond the
reasonable control of the Party, including, without limitation, acts of God, fire, flood, war, civil unrest, labor unrest, or shortage of or inability to obtain material as equipment. 

 

	12.15	Entire Agreement. The terms and conditions herein constitute the entire agreement between the Parties and will supersede all previous agreements, either oral or
written, between the Parties hereto with respect to the subject matter hereof. No agreement or understanding bearing on this Agreement will be binding upon either Party hereto unless it is in writing and signed by the duly authorized officer or
representative of each of the Parties and it expressly refers to this Agreement. 

  

	12.16	Paragraph headings. The headings for each Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand
on the meaning of the language contained in the particular Section. 

  

	12.17	Attorneys’ Fees. In the event of a dispute between the parties hereto or in the event of any default hereunder, the Party prevailing in the resolution of
any such dispute or default will be entitled to recover its actual attorneys’ fees, expert witness fees and other costs incurred in connection with resolving such dispute or default whether in an original action of an appeal.

  

	12.18	Counterparts. This Agreement may be signed in counterparts each of which will be deemed an original, and both of which together will constitute on and the same
instrument. Signatures may be transmitted by facsimile, thereby constituting the valid signature and delivery of this Agreement. 

  

	12.19	Product Marking. Licensee agrees to mark the Licensed Products or their packaging sold in the United States with all applicable U.S. patent numbers and similarly
to indicate “Patent Pending” status. All Licensed Products manufactured in, shipped to, or sold in other countries shall be marked in such a manner as to preserve Institute patent rights in such countries. 

 

	12.20	Survival. The rights and obligations of the Parties under Sections 5, 7.4, 9, 10, 11 and 12 shall survive the termination of this Agreement.

  

	12.21	 No Endorsement. By entering into this Agreement, Institute does not directly or indirectly endorse any product or service provided, or to be
provided, by Licensee 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -22- 

 Nanostring Exclusive License Agreement 
  Page
 23
 of 25 
  

	 	
whether directly or indirectly related to this Agreement. Licensee shall not state or imply that this Agreement is an endorsement by Institute, its faculty members, scientists, researchers,
employees, officers, trustees, directors, and agents. 

 IN WITNESS WHEREOF, the Parties hereto have executed and delivered this
Agreement by their duly authorized officers and representatives effective as of the Effective Date. 
  

									
	Institute for Systems Biology	 		 	NanoString Technologies, Inc.
					
	By:	 	 /s/ Louis R. Coffman
	 		 	By:	 	 /s/ Krassen Dimitrov

					
	Name:	 	 Louis R. Coffman
	 		 	Name:	 	 Krassen Dimitrov

					
	Title:	 	 VP - COO
	 		 	Title:	 	 CEO, President

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -23- 

 Nanostring Exclusive License Agreement 
  Page
 24
 of 25 
  

 APPENDIX A 

LICENSED PATENTS 
  

	1.	US. Patent Application No. 09/898,743, “Methods for Detection and Quantification of Analytes in Complex Mixtures”, filed July 3, 2001.

  

	2.	PCT Patent Application No. PCT/US02/21278, “Methods for Detection and Quantification of Analytes in Complex Mixtures”, filed July 3, 2002.

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -24- 

 Nanostring Exclusive License Agreement 
  Page
 25
 of 25 
  

 APPENDIX B 

LABORATORY NOTEBOOKS 
 Notebook No. 
 184 

273 

347 

378 

481 

508 

  
  

	†	DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 -25-Amendment No. 1 to Exclusive License Agreement

 Exhibit 10.18 
 AMENDMENT NO. 1 
 TO 

EXCLUSIVE LICENSE AGREEMENT 
 This Amendment No. 1 to Exclusive License Agreement (“Amendment”) is entered into on February 5, 2007, by and between the Institute for Systems Biology (the “Institute”), a
Washington nonprofit corporation, having its principal place of business at 1441 No. 34th Street, Seattle, WA 98103 and NanoString Technologies, Inc. (“Licensee”), a Delaware corporation, having its principal place of business at 201
Elliott Ave. W., Suite 300, Seattle, WA 98119. 
 BACKGROUND 
 The Institute and Licensee are parties to that certain Exclusive License Agreement dated February 4, 2004 (“Agreement”). The Parties desire to amend their Agreement as set forth in detail
below. In consideration for the payment set forth in Paragraph 11 below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties expressly agree as follows. 

AMENDMENT 
  

	1.	Amend the Preamble to read as follows: 

 This
Exclusive License Agreement (hereinafter called “Agreement”), is entered into as of February 4, 2004 (“Effective Date”) by and between the Institute for Systems Biology (the “Institute”), a Washington nonprofit
corporation, having its principal place of business at 1441 No. 34th Street, Seattle, WA 98103 and NanoString Technologies, Inc. (“Licensee”). 
 2.     In Article 1, amend Sections 1.1, 1.2, 1.3, 1.4, 1.6, 1.10 and 1.11 to read as follows and add new Sections 1.13 and 1.14: 

 

	 	1.1	 “Licensed Patents” means (a) the patent applications listed on Appendix A as of the Effective Date, (b) any other patent
applications filed by or on behalf of Institute claiming the inventions described and claimed therein, (c) any other patent applications filed by or on behalf of Institute claiming Licensed Know-How, (d) any divisional, continuation, or
continuations-in-part of any of the foregoing applications, but only to the extent that such continuation-in-part applications are directed to subject matter specifically described in and can claim benefit of the priority of a patent application(s)
listed on Appendix A, (e) any patent application owned or controlled by the Institute filed anywhere outside the United States that is directed to the same invention(s) as any and

  

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

	 	
all of the foregoing applications or that, at any time, claimed or can effectively claim priority to any of the foregoing applications, (f) PCT application entitled “Nanoreporters and
Methods of Manufacturing the Use Thereof”, filed December 22, 2006 naming Geiss, G., Ferree, S., Webster, P. and Dimitrov, K. as inventors (Jones Day docket no. 11616-033-228) and its national stage applications, and all patent
applications owned or co-owned by the Institute that claim the benefit of, or priority to, such application; (g) any patent issuing from any of the foregoing applications, and (h) all substitutions, registrations, confirmations,
re-examinations, renewals reissues, extensions, or supplemental protection certificates, of any such patents. All Licensed Patents will be automatically added to Appendix A. 

 

	 	1.2	“End User” means a person or entity that acquires a Licensed Product from Licensee or one of its Sublicensees for re-sale or for use.

  

	 	1.3	“Field” means any and all fields and uses, without limitation. 

  

	 	1.4	“Licensed Product(s)” means any method, composition, or device the manufacture, use, sale, offer for sale, or import of which, but for the license granted in
this Agreement, would infringe, including contributorily infringe, a Valid Claim. 

  

	 	1.6	“Net Sales” means Licensee’s and its sublicensees’ billings for gross amounts invoiced, or if no amount is invoiced, then the amount actually
received for, Licensed Products produced and sold or otherwise disposed of hereunder excluding the sum of the following: 

  

	 	(a)	discounts allowed in amounts customary in the trade; 

  

	 	(b)	sales, tariff duties and/or use taxes directly imposed and with reference to particular sales; 

 

	 	(c)	outbound transportation prepaid or allowed; and 

  

	 	(d)	amounts allowed or credited on returns. 

 No deductions shall be made for commissions paid to individuals whether they be with independent sales agencies or regularly employed by Licensee and on its payroll, or for cost of collections. Licensed
Products shall be considered “sold” when billed out or invoiced. 
  

	 	1.10	“First Commercial Sale” means the first sale to an End User of a Licensed Product after all necessary regulatory approvals have been obtained in the country
of sale, provided, however, that a sale to an Affiliate will not constitute a First Commercial Sale unless the Affiliate is an End User. 

  
 -2-

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

	 	1.11	“Valid Claim” means a claim of (a) a pending patent application included within the Licensed Patents, which claim, together with any amended versions
thereof, has not been pending for longer than six (6) years; or (b) an issued patent included within the Licensed Patents, which claim has not lapsed, been canceled or become abandoned and has not been declared invalid or unenforceable by
an unreversed and unappealable decision or judgment of a court or other appropriate body of competent jurisdiction, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

 

	 	1 13	“Research Product” means any Licensed Product offered for sale or sold for use in research, specifically, a Licensed Product will be a Research Product only
if (a) pursuant to applicable regulatory approvals or rules it can only be sold for research purposes, (b) as offered for sale or sold, it is identified or labeled for research use only, or (c) it is offered for sale or sold to an
entity, such as a university, that primarily conducts research. A Research Product is not a Commercial Product 

  

	 	1.14	“Commercial Product” means any Licensed Product that is not a Research Product. For example, a Licensed Product will be a Commercial Product if
(a) pursuant to applicable regulatory approvals or rules it may be sold for diagnostic or therapeutic purposes, (b) as offered for sale or sold, it is identified or labeled for use for diagnostic or therapeutic purposes, (c) it is
offered for sale or sold to an entity, such as a commercial laboratory or hospital, that primarily performs diagnostic or therapeutic services, or (d) it is the provision of services. 

 

	3.	In Article 2, amend Section 2.1 to read as follows: 

  

	 	2.1	License Grant. The Institute grants to Licensee the exclusive, worldwide license, including the right to grant sublicenses pursuant to Section 2.2, under the
Licensed Patents and Licensed Know-How, and within the Field to make, have made, use, sell, offer for sale and import Licensed Products and to otherwise practice Licensed Patents and use Licensed Know-How in connection with Licensed Products. This
Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of the Institute other than Licensed Patents regardless of whether such patents are dominant or subordinate to Licensed Patents.

  

	4.	In Article 4, amend Sections 4.2 and 4.7 to read as follows: 

  
 -3-

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

	 	4.2	Royalties. (a) Licensee will pay Institute a royalty equal to [†]% of Licensee’s and/or its Sublicensee’s Net Sales of Commercial Products covered
by a Valid Claim at the time of and in the country of sale, and (b) Licensee will pay Institute a royalty equal to [†]% of Licensee’s and/or its Sublicensee’s Net Sales of Research Products covered by a Valid Claim at the time of
and in the country of sale on aggregated gross sales of such Research Products up to [†] dollars and [†]% of Licensee’s and/or its Sublicensee’s Net Sales of Research Products covered by a Valid Claim at the time of and in the
country of sale from and in excess of aggregated gross sales of [†] dollars. 

  

	 	4.7	After “Licensed Products” in line 8, insert “(allocated between Research Products and Commercial Products)”. 

 

	5.	In Article 6, amend Section 6.1 to read as follows: 

  

	 	6.1	Patent Prosecution and Maintenance. From and after the Effective Date of this Agreement, the provisions of this Section 6 will control the filing, prosecution and
maintenance of the Licensed Patents. Licensee will direct and manage (i) the preparation, filing and prosecution of the United States and foreign patent applications arising from or relating to the Licensed Patents (including any interferences
and foreign oppositions) and (ii) the maintenance of the Licensed Patents. The Institute will select the patent attorney, subject to Licensee’s prior written approval, which approval will not be unreasonably withheld and the Institute will
be said attorney’s client. The Institute and Licensee will consult from time to time on patent matters, at which time patent counsel may be changed by mutual agreement of the parties. Effective as of the date of Amendment No. 1 to this
Agreement, Institute selects, and Licensee approves the attorneys of Jones Day (subject to appropriate waivers satisfactory to Institute, Licensee and Jones Day) for handling Licensed Patents. 

 

	 	6.7	Settlement of Infringement Actions. Neither Party may settle any infringement action covered by Section 6.6 in a manner that diminishes the rights or interests of
the other Party without first obtaining the prior written consent (which shall not be unreasonably withheld) of such other Party. In any such settlement, Licensee only shall have the right to grant a sublicense in accordance with Article 2 hereof.

  

	6.	In Article 7, amend Sections 7.2 and 7.4 to read as follows and add new Section 7.6: 

7.2(c)(i) line 9, amend “reasonable” to read —reasonably—. 

  
 -4-

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

	 	7.4	Rights after Termination. At the effective date of any termination of this Agreement pursuant to Section 7.2 hereof for material breach by Licensee, pursuant to
Section 7.3 hereof in the event of bankruptcy by Licensee, or pursuant to Section 7.6 by Licensee, Licensee will immediately cease using Inventions covered by any Valid Claim of an issued patent within Licensed Patents; provided, however,
that Licensee may for six (6) months dispose of any Licensed Products actually in the possession of Licensee or as to which it has made irrevocable commitments to sell or have made prior to the date of termination, subject to Licensee’s
paying to the Institute running royalties in accordance with Section 4.2 with respect thereto and otherwise complying with the terms of this Agreement.” 

 

	 	7.6	Termination At Will. Licensee shall have the right to terminate this Agreement, in whole or in part (with respect to any country or Licensed Patent) upon thirty
(30) days written notice to Institute. Section 7.4 will not apply to partial termination of this Agreement pursuant to this Section 7.6. 

  

	7.	Amend Article 8 to read as follows: 

  

	 	8.	Assignability. The rights and licenses granted by Institute in this Agreement are personal to Licensee and may not be assigned or otherwise transferred without the
written consent of Institute (such consent not to be unreasonably withheld), provided, however, that Licensee may, without such consent but with notification, assign this Agreement and its rights and obligations hereunder to any of its Affiliates,
or in connection with the transfer or sale of all or substantially all of its business relating to Licensed Products or its merger, acquisition or other consolidation with or into another party other than a transfer or sale in connection with
Licensee’s insolvency, dissolution, bankruptcy or receivership proceedings. Any permitted assignee shall assume all rights and obligations of its assignor under this Agreement. Any attempted assignment or transfer without consent under
circumstances requiring the Institute’s consent shall be void and shall automatically terminate all rights of Licensee under this Agreement. 

  

	8.	Amend Article 9 to read as follows: 

  

	 	9.	Governmental Compliance. Licensee will, at all times during the term of this Agreement and for so long as it sells Licensed Products for which royalties are due
Institute pursuant to this Agreement, comply and require its sublicensees to comply with all laws that control the import, export, manufacture, use, sale, marketing, distribution and other commercial exploitation of Licensed Products or any other
activity undertaken pursuant to this Agreement. 

  
 -5-

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

	9.	In Article 11, amend Licensee’s address as follows: 

 In the case of Licensee: 
 President 

NanoString Technologies, Inc. 
 201 Elliott Avenue W., Suite 300 
 Seattle, WA 98119 

 

	10.	In Article 12, amend Sections 12.3, 12.14, 12.17 and 12.20 to read as follows: 

 

	 	12.3	Indemnity. Licensee will defend, indemnify and hold Institute harmless against all liabilities, demands, damages, expenses (including reasonable attorneys’ fees
and costs), or losses in connection with any claims, suits, actions, demands or judgments arising out of any theory of liability (including, without limitation, actions in the form of tort, warranty, or product liability, and regardless of whether
such action has any factual basis) (“Claims”) concerning (1) any product, process or service that is made, used, sold, offered for sale, imported, performed or otherwise disposed pursuant to any right or license granted under this
Agreement, and (2) the negligent acts or omissions or willful misconduct of Licensee, sublicensees, or customers, employees or agents of the foregoing in connection with the exercise of its/their respective rights under this Agreement, except
to the extent any such Claim results from the gross negligence or willful misconduct of any indemnitee hereunder or the breach by Institute of any warranty, representation or agreement made by Institute hereunder. 

 

	 	12.14	Force Majeure. No breach hereunder will result by reason of delay in performance of a Party caused by force majeure, that is, circumstances beyond the reasonable
control of such Party, including, without limitation, acts of God, fire, flood, war, civil unrest, labor unrest, or shortage of or inability to obtain material as equipment. The Party suffering force majeure shall provide prompt written notice
thereof to the other Party. If as a result of force majeure, performance by Licensee under this Agreement is excused for a continuous period of 180 days, Institute may terminate this Agreement on written notice to Licensee. 

 

	 	12.17	Attorneys’ Fees. In the event of a dispute between the parties hereto or in the event of any default hereunder, the Party prevailing in the resolution of any such
dispute or default will be entitled to recover its actual attorneys’ fees, expert witness fees and other costs incurred in connection with resolving such dispute or default whether in an original action or an appeal. 

  
 -6-

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

	 	12.20	Survival. The rights and obligations of the Parties under Sections 5, 7.1, 7.4, 9, 10, 11 and 12.1 to 12.6, 12.10, 12.11, 12.16, 12.17 and 12.20 (in accordance with
their provisions) shall survive the termination of this Agreement. 

  

	11.	Appendix A. Replace original Appendix A with the Updated Appendix A attached hereto. 

 

	12.	NO OTHER CHANGES. Except for the agreed upon amendments set forth herein, in all other respects the remaining terms and conditions of the Agreement shall remain in full
force and effect as written. If there is a conflict between any provision of the Agreement and a provision of this Amendment, the terms of this Amendment shall prevail. 

 

	13.	In consideration for this Amendment, Licensee agrees to pay Institute a one time fee of $[†] to cover costs incurred by the Institute for its own efforts and its
outside legal counsel’s fees in connection with this Amendment. This fee shall be due and payable within 30 days of the effective date of this Amendment No. 1 as first written above. 

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Amendment by their duly authorized officers and representatives effective as of
the date first written above. 
  

									
	Institute for Systems Biology	 		 	NanoString Technologies, Inc.
					
	By:	 	/s/ Leroy Hood	 		 	By:	 	/s/ H. Perry Fell
	Name: Leroy Hood	 		 		 	Name: H. Perry Fell
	Title: President	 		 		 	Title: C.E.O.

  
 -7-

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 NanoString Exclusive License Agreement 
 Page 13 of 14 
 UPDATED APPENDIX A 

Licensed Patents 
  

									
	 Inventor
	  	 Country
	  	 Application No.
	  	 Filed
	  	 Title

	Dimitrov, K.	  	U.S.	  	09/898,743	  	7/3/01	  	Methods for Detection and Quantification of Analytes in Complex Mixtures
	 Dimitrov, K.
 Dunaway,
D.
	  	U.S.	  	10/542,458	  	7/3/02	  	Methods for Detection and Quantification of Analytes in Complex Mixtures
	 Dimitrov, K.
 Dunaway,
D.
	  	Canada	  	2,452,712	  	7/3/02	  	Methods for Detection and Quantification of Analytes in Complex Mixtures
	 Dimitrov, K.
 Dunaway,
D.
	  	Australia	  	2002327202	  	7/3/02	  	Methods for Detection and Quantification of Analytes in Complex Mixtures
	 Dimitrov, K.
 Dunaway,
D.
	  	Japan	  	2003-509840	  	7/3/02	  	Methods for Detection and Quantification of Analytes in Complex Mixtures
	 Dimitrov, K.
 Dunaway,
D.
	  	EP	  	02763230.6	  	7/3/02	  	Methods for Detection and Quantification of Analytes in Complex Mixtures
	 Dimitrov, K.

Dunaway, D.
	  	PCT	  	PCT/US02/21278	  	7/3/02	  	Methods for Detection and Quantification of Analytes in Complex Mixtures
	 Geiss, G.
 Ferree,
S.
 Webster, P.

Dimitrov, K..
	  	PCT	  	 To Be Assigned
 JD
Docket No. 11616-033-228
	  	12/22/2006	  	 Nanoreporters and Methods of Manufacturing and Use Thereof
 (Co-owned by NanoString and Institute)

  

 † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]